Evidence map›Paper›PMID 41752887›Full record

ReviewLife (Basel, Switzerland)2026

Luminescence-Based Strategies for Detecting β-Lactamase Activity: A Review of the Last Decade.

Michał Jakub Korytkowski, Anna Baraniak, Alicja Boryło, Paweł Rudnicki-Velasquez

Erratum issuedAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Michał Jakub KorytkowskiDepartment of Pharmaceutical Microbiology and Laboratory Diagnostics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.ORCID 0009-0003-9144-9742
Anna BaraniakDepartment of Pharmaceutical Microbiology and Laboratory Diagnostics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.ORCID 0000-0001-9996-8553
Alicja BoryłoDepartment of Chemistry and Radiochemistry of Environment, Faculty of Chemistry, University of Gdansk, Wita Stwosza 63 Str., 80-308 Gdansk, Poland.
Paweł Rudnicki-VelasquezDepartment of Falsified Medicines and Medical Devices, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.ORCID 0000-0003-0368-0112

Funding

Narodowy Instytut Leków This work was financed by internal funding from the National Medicines Institute
6 · The paper itself

Abstract

Rapid detection of β-lactamase activity is becoming increasingly important as β-lactam resistance spreads at an alarming rate and conventional diagnostics often require several hours to deliver actionable results. Over the past decade, methods based on luminescence, bioluminescence, chemiluminescence, and fluorescence have become powerful tools for the functional assessment of resistance resulting from β-lactamase activity. These approaches provide highly sensitive, activity-based readouts, often within minutes, and frequently rely on simple optical instrumentation. In this review, we summarize recent developments in luminescent probe design between 2015 and 2025, with emphasis on reaction mechanisms, analytical performance, and the ability of these systems to discriminate between different β-lactamases, including narrow-spectrum enzymes, AmpC, ESBL, and carbapenemases. We also discuss their applications in bacterial cultures, clinical isolates, complex biological matrices and, in some cases, in vivo models. While luminescent assays are not yet positioned to replace standard susceptibility testing, they offer a practical and increasingly robust complement to culture-based and molecular methods. The emerging trends highlighted here, such as self-immobilizing fluorogenic probes, chemiluminescent relay systems, nanomaterial-based sensors and AI-assisted mobile platforms, suggest that luminescent β-lactamase detection could play a meaningful role in future rapid diagnostics and resistance surveillance.

Indexed as

bioluminescencecarbapenemaseschemiluminescenceESBLfluorescenceluminescencerapid diagnosticsβ-lactamasesβ-lactam resistance

Identifiers

PMID41752887
PMCPMC12941553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.